BRCA2 and leiomyosarcoma: Furthermore, Hensley et al. reported clinical benefit in all five BRCA2-mutant uLMS patients treated with PARP inhibitors, further supporting the potential actionability of HRR alterations in uterine leiomyosarcoma [19].